%0 Journal Article
%T NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.
%A Daly MB
%A Pal T
%A Maxwell KN
%A Churpek J
%A Kohlmann W
%A AlHilli Z
%A Arun B
%A Buys SS
%A Cheng H
%A Domchek SM
%A Friedman S
%A Giri V
%A Goggins M
%A Hagemann A
%A Hendrix A
%A Hutton ML
%A Karlan BY
%A Kassem N
%A Khan S
%A Khoury K
%A Kurian AW
%A Laronga C
%A Mak JS
%A Mansour J
%A McDonnell K
%A Menendez CS
%A Merajver SD
%A Norquist BS
%A Offit K
%A Rash D
%A Reiser G
%A Senter-Jamieson L
%A Shannon KM
%A Visvanathan K
%A Welborn J
%A Wick MJ
%A Wood M
%A Yurgelun MB
%A Dwyer MA
%A Darlow SD
%J J Natl Compr Canc Netw
%V 21
%N 10
%D 2023 10
%M 37856201
%F 12.693
%R 10.6004/jnccn.2023.0051
%X The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic/likely pathogenic (P/LP) variants associated with increased risk of breast, ovarian, pancreatic, and prostate cancer, including BRCA1, BRCA2, CDH1, PALB2, PTEN, and TP53, and recommended approaches to genetic counseling/testing and care strategies in individuals with these P/LP variants. These NCCN Guidelines Insights summarize important updates regarding: (1) a new section for transgender, nonbinary and gender diverse people who have a hereditary predisposition to cancer focused on risk reduction strategies for ovarian cancer, uterine cancer, prostate cancer, and breast cancer; and (2) testing criteria and management associated with TP53 P/LP variants and Li-Fraumeni syndrome.